Eikon Therapeutics, a late-stage clinical biopharmaceutical company, has priced its upsized initial public offering of 21,177,600 shares at $18.00 per share, expecting gross proceeds of approximately $381 million before fees. The underwriters have a 30-day option to purchase an additional 3,176,640 shares. The company's shares are expected to begin trading on the Nasdaq Global Select Market on 5 February 2026 under the ticker symbol "EIKN". The offering is scheduled to close on or about 6 February 2026, subject to customary closing conditions. J.P. Morgan, Morgan Stanley, BofA Securities, Cantor and Mizuho are serving as joint book-running managers for the offering. Eikon focuses on developing innovative medicines for oncology and other areas of high unmet medical need.

Integrated Biosciences names Daniel J. Anderson CSO. Anderson will oversee the company's scientific strategy and pipeline development. Integrated Biosciences has a new Chief Scientific Officer (CSO), naming Daniel J. Anderson, PhD, to the post. Anderson joins from Eikon Therapeutics, and previously worked for Recursion Pharmaceuticals, Cleave Biosciences, and Genentech. Based in Redwood City, Calif., Integrated Biosciences is a biotechnology company combining the fields of synthetic biology, chemistry, and AI. By doing this, the company discovers small-molecule therapeutics for age-related diseases. Details of new cso's role. Anderson's role is to oversee Integrated Biosciences' scientific strategy and pipeline development. In this way, the company says Anderson's leadership will help build upon its proprietary platform. Integrated Biosciences said Anderson has advanced 10 programs into the clinic in his career. In his previous work, he has focused on cutting-edge technology and data science approaches to drug discovery. "Integrated Biosciences has built a platform that tightly couples precise biological perturbation with high-content measurements and AI-driven learning," Anderson said. "The exceptional platform has produced a pipeline with real promise for age-related diseases. I'm excited to help accelerate translation from discovery to the clinic and facilitate bringing important new medicines to patients." Integrated Biosciences leaders respond. Felix Wong, PhD, Integrated Biosciences co-founder and CEO, applauded the move. "[Anderson's] decision to join Integrated Biosciences underscores the strength of our science, platform, and the opportunity ahead," Wong said. "His track record of building high-growth teams at Eikon Therapeutics and his scientific rigor position him perfectly to help lead." Another co-founder, Max Wilson, PhD, will move into the role of Chief Technology Officer. This post will focus on advancing Integrated Biosciences' core technology platform, including next-generation AI-enabled discovery. "[Anderson] brings over 20 years of experience in biotechnology and drug discovery," Wilson said. "I'm excited to focus on scaling our technology platform alongside him."

Eikon files for an IPO in major test for whether biotech's rally will take the next step. Senior biopharma correspondent. Eikon Therapeutics has filed for an IPO, in what would be a bellwether for whether the optimism that has rallied the... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.